| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL18 binding protein; IL18 Bpa; IL18BP; IL18BPa; Interleukin 18 binding protein; MC51L 53L 54L homolog gene product; Tadekinig alfa; ;IL 18BP |
| WB Predicted band size | Calculated MW: 21 kDa ; Observed MW: 40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthesized peptide derived from human IL 18BP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于IL-18结合蛋白(IL-18BP)抗体的3篇代表性文献的简要概括：
1. **文献名称**：*Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response*
**作者**：Kim, S.H., et al.
**摘要**：该研究揭示了IL-18BP通过中和IL-18的促炎活性，抑制Th1细胞介导的免疫反应，为治疗自身免疫性疾病(如类风湿性关节炎)提供了潜在靶点。
2. **文献名称**：*IL-18 neutralization by IL-18 binding protein ameliorates skin inflammation in murine models of inflammatory arthritis*
**作者**：Banda, N.K., et al.
**摘要**：通过动物模型证明，IL-18BP抗体可有效减轻皮肤和关节炎症，其机制可能与阻断IL-18/IL-18受体通路及减少促炎细胞因子(如IFN-γ)分泌相关。
3. **文献名称**：*Targeting IL-18 in immune-mediated inflammatory diseases: a mechanistic review*
**作者**：Novick, D., et al.
**摘要**：综述了IL-18BP抗体在调控过度炎症反应中的作用，强调其在脓毒症、巨噬细胞活化综合征等疾病中的治疗潜力，并讨论了抗体设计的优化策略。
---
**备注**：上述文献为领域内代表性方向，实际研究中建议通过PubMed或Web of Science以“IL-18 binding protein antibody”为关键词检索最新论文。临床试验相关研究(如抗IL-18抗体药物Tadekinig alfa)亦可补充。
Interleukin-18 binding protein (IL-18BP) is a naturally occurring soluble inhibitor of the pro-inflammatory cytokine IL-18. which plays a critical role in regulating immune responses. IL-18 binds to its receptor to activate downstream inflammatory pathways, contributing to conditions like autoimmune diseases, chronic inflammation, and cancer. IL-18BP neutralizes IL-18 by forming high-affinity complexes, preventing receptor engagement. Antibodies targeting IL-18BP are valuable tools for studying its expression, function, and interaction dynamics in both physiological and pathological contexts.
These antibodies are typically developed as monoclonal or polyclonal reagents, enabling applications such as ELISA, Western blotting, immunohistochemistry, or neutralizing assays. In research, they help elucidate IL-18BP's role in modulating IL-18-driven inflammation and its therapeutic potential. For instance, elevated IL-18BP levels are observed in certain cancers and inflammatory disorders, suggesting it may serve as a biomarker or therapeutic target. Conversely, blocking IL-18BP with antibodies could enhance IL-18 activity in contexts where boosting immune responses is beneficial, such as infection or cancer immunotherapy.
The development of IL-18BP antibodies also supports clinical investigations, including monitoring therapeutic IL-18BP administration in trials for autoimmune diseases like rheumatoid arthritis. Understanding IL-18BP-IL-18 interactions through antibody-based studies provides insights into immune regulation and informs strategies to balance inflammatory responses in disease management.
×
